PRESS-RELEASE ·Filed Apr 16, 2026
Press release: announcement
Actionable Insight • Neutral
No immediate trading implications. Monitor upcoming clinical trial updates or financing announcements, which would be more material catalysts for this micro-cap biotech.
Final — all horizons settled through T+60d ⚠ clustered
EVAX ▼ -27.05% at T+60d
NEUTRAL call ✗ call lost -27.05% · α vs SPY -34.10% · entry $4.14 → $3.02
T+1d
+7.49%
call +7.49% · α +6.27%
$4.45
settled 6mo ago
T+5d
+2.66%
call +2.66% · α +1.67%
$4.25
settled 5mo ago
T+20d
+0.48%
call +0.48% · α -5.33%
$4.16
settled 5mo ago
T+60d
-27.05%
call -27.05% · α -34.10%
$3.02
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Evaxion held its Annual General Meeting, approving the 2025 Annual Report and re-electing four board members while adding one new director. The filing is a routine corporate governance update with no material financial or strategic developments disclosed.
Key Facts
- Annual General Meeting held on April 16, 2026
- 2025 Annual Report approved
- Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner, and Roberto Prego Pineda re-elected to Board
- Jens Bitsch Nørhave newly elected to Board
- No changes to executive leadership or company strategy announced
Financial Impact
No financial impact
Risk Factors
- Forward-looking statements highlight risks related to funding needs and clinical development
- Small market cap ($35M) increases volatility and sensitivity to future dilution
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3275638 |
36 reports for EVAX
100% Hit rate best @ T+5▲ +22.94%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
Showing 10 of 36
US Market Status
Market Open — Closes in 39m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access